Logotipo de Valence
populares
Iniciar sesión
Loading data for GPCR — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

Structure Therapeutics In...

NasdaqGM: GPCR · Precio en tiempo real · USD
50.52
-3.61 (-6.67%)
Al cierre: Aug 21, 2026, 8:00 PM
49.09
+0.00%
Fuera de horario: 4:01 PM

El precio, las cifras principales y las últimas noticias, en un solo sitio.

Structure Therapeutics Inc. (GPCR): cotización, análisis y datos

-6.67%

No hay datos disponibles

Precio de compra36.54
Capitalización de mercado3.5B
Ingresos (TTM)n/a
Beneficio neto (TTM)-214.84M
-1.51
-3.03
n/a
-23.21
P/B (TTM)2.58
P/S (TTM)n/a
Fecha de resultadosNov 5, 2026
Precio de venta64
Volumen1,429,142
Volumen medio (20D)714,993
Abierto54.15
Anterior Cerrar54.13
Rango del día50.33 - 54.32
Rango de 52 semanas18.26 - 94.90
analistan/a
Precio objetivon/a
Dividendosn/a
Fecha ex dividendon/a

Acerca de GPCR

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. Th...

[Leer más]
Industria Biotechnology
Sector Healthcare
IPO Fecha Feb 3, 2023
Empleados 281
Bolsa de Valores NasdaqGM
Símbolo bursátil GPCR
Sitio web https://structuretx.com
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Structure Therapeutics fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -141.2M, un aumento de 15.24%.

Estados financieros

Sorpresa de resultados

Structure Therapeutics ha publicado sus resultados trimestrales en Aug 6, 2026:
  • Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
  • EPS de -0.49 falla las estimaciones por -0.11, con -36.11% Disminución interanual.

    • Próxima publicación de resultados

    Está previsto que Structure Therapeutics Inc. publique sus resultados el Nov 5, 2026, durante el horario de mercado.
    Los analistas proyectan ingresos de ... Actualizar
    news image

    1 mes hace · Insider Monkey

    Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now

    Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 7, Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Structure Therapeutics I...

    news image

    1 mes hace · 24/7 Wall St.

    After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching

    Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural ...

    news image

    2 meses hace · Insider Monkey

    H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)

    Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ...

    news image

    2 meses hace · Insider Monkey

    Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron

    Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, sh...

    news image

    2 meses hace · Simply Wall St.

    Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?

    Structure Therapeutics recently reported in Nature Medicine and at the American Diabetes Association’s 86th Scientific Sessions that its oral GLP-1 receptor agonist aleniglipron achieved statistically...

    Página 1 de 2